Thermo Fisher lanza instrumento NGS marcado CE-IVD para pruebas de diagnóstico
Actualizado el 13 Apr 2022
Thermo Fisher Scientific (Waltham, MA, USA) has launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in as little as a single day.
Designed for use in clinical laboratories, the fully validated system enables users to perform both diagnostic testing and clinical research on a single instrument. In support of increasing physicians’ access to rapid NGS results, Thermo Fisher is also developing a complete sample-to-report diagnostic workflow and a portfolio of clinically validated assays, including those for comprehensive genomic profiling and hemato-oncology, on the Genexus System.
“Next-generation sequencing has become an essential tool to bring the promise of precision medicine therapies to patients. With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital – including regional and community hospitals – can bring NGS in-house, giving clinicians access to timely, comprehensive genomic profiling results,” said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “With faster answers, the results can aid clinicians in their patient management decision making which may include therapeutic options.”
Enlaces relacionados:
Thermo Fisher Scientific
